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BACKGROUND: Hematological complications such as 
Zidovudine(ZDV) associated anemia are among the commonly 
reported adverse drug reactions of Antiretroviral Therapy(ART). 
Little is known about ZDV associated anemia in developing 
countries like Ethiopia.  
METHODS: Comparative retrospective cohort study was conducted 
at the ART Clinic of St. Paul Hospital Millennium Medical College 
from February 2011 to December 2012 to characterize anemia 
among HIV/AIDS patients initiated with ZDV and non-ZDV 
containing ART regimens. In each group, 197 HIV infected adults 
who had complete medical records were included. Medical records 
of participants were reviewed using pre-tested data collection 
format. Data were analyzed using SPSS version 19 for windows. 
For all statistical significance tests, the cut-off value was P<0.05.  
RESULTS: Among ZDV group, anemia prevalence was 20.8 % 
(41/197), 33.5%(66 /197) and 13%(19/146) at baseline, six and 
twelve months of ART follow-up, respectively.On the other hand  in 
non-ZDV group, anemia was present among 44.2% (87/197), 18.3% 
(36/197) and 12.4% (25 /202) of participants at baseline, six and 
twelve months of ART follow-up, respectively. After six months of 
follow-up, ZDV associated anemia was present among 32.7% 
(51/156) of the participants, and 43.1% of them  were severe while 
about 45.2% were macrocytic type. Zidovudine group participants 
were 3.34 times more likely to develop severe anemia than non-
ZDV group, P< 0.001.  
CONCLUSION: The prevalence, severity and characteristics of 
anemia were different between ZDV and non-ZDV group 
participants at different follow-up periods of ART. Zidovudine had 
significant contribution to severe anemia incidence after six months 
of ART; thus, hemoglobin level monitoring with red cell indices is 
suggested for improved detection of zidovudine associated anemia.   
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Anemia is the most common and serious 
hematological complication of both Human 
Immunodeficiency Virus (HIV) infection and its 
treatment (1, 2). Depending on the study setting, 
the prevalence of anemia in HIV patients varies 
considerably.  Close to 95% of HIV infected 
patients before the initiation of Antiretroviral 
Therapy (ART) and up to 46% of patients taking 
ART develop anemia at some point during the 
course of their disease(3,4). Anemia in these 
patients might be caused by a wide range of 
etiologic factors leading to decreased red blood cell 
(RBC) production, increased RBC destruction, or 
ineffective RBC production (5,6). Studies 
indicated that anemia among ART naïve 
HIV/AIDS patients was associated with much 
faster rate of disease progression and decreased 
quality of life, and was a strong prognostic marker 
for death (7-9). 
         Antiretroviral Therapy was generally taken 
as an effective treatment for reduction of anemia in 
HIV infection by inhibiting the progress of the 
disease (10). However, Zidovudine (ZDV), an 
element of some ART regimens and one of the 
first-line antiretroviral drugs for treating HIV 
infected adults in low resource countries (11), is 
identified as the commonest cause of drug 
associated anemia (12,13). The proposed 
mechanism of anemia causation during ZDV 
therapy is inhibition of hemoglobin synthesis, 
globin gene transcription and proliferation of blood 
cell progenitor in a time and dose dependent 
fashion (12-14). A study conducted in the United 
States of America to compare the incidence of 
anemia in patients treated with ZDV containing 
and non-ZDV containing ART revealed that 
patients initiated with ZDV containing ART were 
at greater risk of developing new anemia or 
worsening anemia than patients initiated with non-
ZDV containing ART drug regimens (15).  
          Although the current World Health 
Organization (WHO) ART guideline did not 
recommend ZDV containing regimens as a 
preferred regimen (16), some resource constrained 
countries like Ethiopia continue to use ZDV-based 
regimens as an alternative first line drug regimen 
(17). Studies indicated that side effects of ART 
drugs studied in western (developed) nations may 
not be representative of developing countries such 
as Ethiopia since socio-economic constraints, host 
genetics, co-morbid conditions and nutritional 
intake are the risk factors for adverse drug 
reactions (18).     
              The magnitude and characteristics of ZDV 
associated anemia among Ethiopian patients has 
not been well documented. Thus, the aim of this 
study was to provide a comparative information 
about the magnitude, severity and characteristics of 
anemia among HIV/AIDS patients initiated with  
ZDV and non-ZDV containing ART regimens at 




Study Setting and Population: A comparative 
retrospective study was conducted by reviewing 
hospital data of patients who were receiving ART 
at the ART Clinic of St. Paul Hospital Millennium 
Medical College(SPHMMC), Addis Ababa 
Ethiopia. The ART Clinic of the hospital started 
provision of ART service in 2003. A well recorded 
HIV/AIDS data were available at the hospital, and 
data from February 2011 to December 2012 were 
used for this study. 
         All eligible HIV/AIDS patients who initiated 
ART between February 2011 and December 2012; 
had complete demographic, laboratory and clinical 
records; and had at least six months of ART 
follow-up at the ART Clinic of SPHMMC were 
included.  Study participants were assigned into 
two groups based on presence or absence of ZDV 
in the starting ART regimen; ZDV containing ART 
initiated group (ZDV group) and non-ZDV 
containing ART initiated group (non-ZDV group). 
Hence, a total of 394 HIV infected individuals’ 
data, 197 in each group, were assessed. Data of 
pregnant HIV/AIDS patients and that of those who 
had identified opportunistic infections were 
excluded from the study since both could lead to 
anemia themselves.  
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Before collection of the data, a data extraction tool 
was prepared and pre-tested. Two ART trained  
nurses  and one laboratory technologist were 
selected and  given a one day training on the data 
extraction tool and how to collect data from 
registers to ensure no selection or information bias 
would be introduced at the time of data collection. 
The principal investigator supervised the data 
collectors and examined the tools for accuracy and 
completeness. 
             The data collection tool contains the 
participants’ demographic variables, ART 
outcome, WHO clinical stage, type of ART 
regimen and immune-hematological parameters.  
Each variable was carefully extracted from ART 
log book, patient follow-up cards and laboratory 
information system computer records at baseline 
(before ART initiation), after six months and 12 
months of ART follow-up. In the absence of same 
day data, the data which was collected in the 
closest day before the date of ART initiation (up to 
one week before date of ART initiation) was 




Demographic and Clinical Characteristics of 
the Study Participants: In this study, a total data 
of 394 HIV infected individuals (197 in ZDV and 
197 in non-ZDV group) were included. The 
majority of the study participants were females 
(60.4% vs. 67.5% in ZDV and non-ZDV group, 
respectively). At baseline, ZDV group participants 
were relatively younger with median (interquartile 
range) (IQR) age of 34.0[28-40] vs. 35.0[29-42] 
years, were at advanced WHO clinical stage (stage 
III or IV) (54.3% vs. 63.4%) and had significantly 
higher proportion of working patients (90.4% vs. 
78.7%) (P=0.002) than non-ZDV group 
participants, respectively (Table 1). 
At treatment initiation, ZDV group 
participants had significantly higher  median 
weight with  median [IQR] of 55[49.5-62.0] vs. 
52[46-60.5] kg (P=0.002) than non-ZDV group 
participants. Similarly, they had also higher 
median hemoglobin concentration with median 
[IQR] of 13.7 [12.4-14.7] g/dl vs. 12.5[10.8-13.9] 
g/dl) (P=0.001) and higher median MCHC with 
median [IQR] of 33.25[32.1-34.32] vs. 32.4[31.5-
33.72] g/dl (P=0.01) than non-ZDV graoup  
participants (Table 1).    
         After six months of follow-up, a total of 46 
individuals were lost from follow-up (dropouts); 
majority of them (25/46) were from non-ZDV 
group. Among the dropouts, 21.7% (10/46) were 
anemic either at baseline or at six months of follow-
up. There was also switching from ZDV group to 
non-ZDV group and vice versa, thirty one and one 
participant, respectively. 
Magnitude, Severity and Characteristics of 
Anemia: Anemia  was present among 20.8 % 
(41/197) and 33.5% (66/197)  of ZDV group 
participants at baseline and six months of ART 
follow-up, respectively, which showed a statistically 
significant increment of anemia prevalence, 
P=0.006. On the other hand, in the non-ZDV group,  
anemia was present among 44.2% (87/197) and 
18.3% (36/197) of patients at baseline and six 
months of follow up respectively, with statistically 
significant decrease of anemia prevalence, 
P<0.001(Table 2). 
Due to loss to follow-up and switching after 
six months of treatment, number of participants at 
twelve months of follow-up in the ZDV and non-
ZDV groups were 146 and 202, respectively. Of  
these participants, anemia was present among 
19(13%) and 25(12.4%) participants in  ZDV and 
non-ZDV group, respectively (Table 2).  
In the ZDV group, anemia was 
predominantly mild at baseline (65.9%) and after 
twelve months (73.7%) of ART but severe (42.4%) 
after six months of ART. The majority of the 
anemia at baseline and after six months of follow-
up were of normocytic type (63.4% and 53.1%, 
respectively) while macrocytic anemia (68.4%) was 
the dominant finding after twelve months of follow-
up (Table 2). 
In the non-ZDV group, anemia was of 
moderate type at baseline in the majority of them 
(55.2%), but mild anemia was dominant after six 
months (58.3%) and twelve months (56%) of 
follow-up. In this group, normocytic anemia was the 
dominant finding at baseline (75.8%), after six 
months (75.0%) and twelve months (64%) of ART 
follow-up (Table 2). 
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Table 1: Comparison of demographic and immune-hematological characteristics of ZDV group and non-




Characteristics  ZDV group  Non-ZDV group  P-value 
Gender, n (%) 
            Male  









Age (years), median(IQR) 34.0(28-40) 35.0(29-42) 0.48 
Age group (years), n(%) 
             18-24 
             25-34 
            35-44 
             ≥45	













WHO Stage, n (%) 
      Less advanced (Sage I or II) 









Weight (in Kg),median(IQR) 55(49.5-62.0) 52(46-60.5) 0.002 
Weight group, n(%) 
       ≥50 kg 










       Working  









CD4+T-cell( cells/mm3),median (IQR) 149(82-199)  155(88-201) 0.762 
CD4+T-cell (cells/mm3), n(%) 
       <50 
      50-199 
      200-349 













Hemoglobin conc.(g/dl),median(IQR) 13.7(12.4-14.7) 12.5(10.8-13.9) 0.001 
MCV(fl),median(IQR) 88(83.3-92.7) 87.9(82.8-92.15) 0.9999 
MCHC(g/dl),median(IQR) 33.25(32.1-34.37) 32.4(31.5-33.77) 0.01 
Incident Anemia: Incident anemia after treatment 
initiation was assessed by restricting the analysis 
on data of participants who were non-anemic at 
baseline. Accordingly, a total of 266 participants, 
156 in ZDV group and 110 in non-ZDV group, 
were free from anemia at baseline. Similarly, 174 
participants, 89 among the ZDV group and 85 
among non-ZDV group, were free from anemia 
both at baseline and six months of follow-up. 
Incident anemia at six months of follow-up was 
recorded in 32.7% (51/156) and 8.2% (9/110) of 
participants among the ZDV group and the non-
ZDV group described as ZDV associated and 
non-ZDV associated anemia, respectively. After 
twelve months of follow-up, the prevalence of 
ZDV associated and non-ZDV associated incident 
anemia was 12.4 % (11/89) and 7.1% (6/85), 
respectively (Table 3).	
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Table 2: Prevalence, severity and type of anemia among ZDV and Non-ZDV group participants at 
baseline, six and twelve months of ART follow up at ART clinic of SPHMMC, from February 2011-
December	2012.		
	
†The number increased due to drug regimen shift from ZDV group to non-ZDV group 
**The number of participants decreased due to regimen shift from ZDV group to non-ZDV group and lost  to follow-up 
	
Incident anemia at six months of ART follow-up 
had a significant association with ZDV containing 
ART, P<0.001; baseline body weight, P=0.047 and 
age of participants, P=0.017.  However, it did not 
show significant association with sex, P=0.854; 
WHO clinical stage, P=0.426; functional status, 
P=0.93; and baseline CD4 T-cell count, P=0.182 
[Table 4]. 
           The majority of the incident anemia cases 
among the ZDV group were severe (43.1%) after 
six months and mild (63.6%) after twelve months of 
follow-up. In the non-ZDV group, 88.9% and 
83.3% of incident anemia cases were mild at six and 
twelve months of follow-up, respectively (Table 3).  
Zidovudine group participants were 3.34 times more 
likely to develop severe anemia than non-ZDV 
group participants, RR=3.34, 95% CI of [1.95, 
5.52], P< 0.001. 
         The majority of incident anemia cases were 
normocytic type (58.3%) after six months and 
macrocytic (53%) after twelve months of ART 
follow-up. There was a remarkably higher 
proportion of  macrocytic anemia cases among the 
ZDV group (45.2% and 72.7%) than the non-
ZDV group (11.1% and 16.7%) after six and 
twelve months of follow-up, respectively (Table 
3). Macrocytic anemia development after six 
months of follow-up had a significant association 
with ZDV containing ART, and the risk of 
macrocytosis in ZDV group participants was 2.1 
times than that of their non-ZDV  counterparts, 









Characteristics  Study participants 













Anemia prevalence n(%) 41(20.8) 66(33.5) 19(13) 87(44.2) 36(18.3) 25(12.4) 
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Table 3: Comparative prevalence, severity and characteristics of incident anemia among ZDV group and 
Non-ZDV group participants after six and twelve months of ART follow up at ART clinic of SPHMMC from 




The aim of this study was to provide comparative 
information about the magnitude and 
characteristics of anemia among HIV/AIDS 
patients initiated with ZDV and non-ZDV 
containing ART drug regimens. Our study 
showed that at treatment initiation anemia was 
present among 20.8% and 44.2% of ZDV 
containing and non-ZDV containing ART drug 
regimens initiated participants, respectively. The 
higher prevalence of anemia among the non-ZDV 
group was a reflection of the recommendation of 
the national HIV/AIDS treatment guideline of 
Ethiopia which indicates initiation of   patients 
with lower hemoglobin concentration on non-
ZDV containing ART drug regimens (21). This 
study revealed that in the majority of the cases, 
anemia was mild among the ZDV group (65.9%) 
and moderate (55.2%) among the non-ZDV 
group. In addition, in 92% of the cases of anemia 
were characterized by normocytic or microcytic 
RBC morphology. This was in agreement with 
other studies which reported that anemia among 
ART naïve HIV/AIDS patients was mostly mild 
and had microcytic or normocytic blood picture 
which is the feature of anemia of chronic diseases 
(22-24). 
           Different studies report controversial 
results on the status of anemia during ART 
follow-up. Some studies claim that treating HIV 
infection with antiretroviral drugs generally 
improves anemia, even when specific treatment 
for anemia is not provided (10, 25-27). In support 
of this, a study conducted in South Africa 
revealed improvement of hemoglobin levels 
regardless of magnitude of immunosuppression 
and ART initiating regimens (28).  On the other 
hand, several studies found that ART regimens 
containing ZDV cause anemia due to the 
heamatotoxic effect of ZDV which is observed in 
most of the patients within 3-6 months and is 
reversible (15,18, 29,30).  This study showed that 
among the non-ZDV group, anemia improved 
from prevalence of 44.2% at baseline to 18.3% 
after six months and to 12.4 % after twelve 
 
Characteristics 
Total ZDV group Non-ZDV group 
After  6  After 12  After 6  After 12  After 6  After 12  
Month months months months month months 
Number of participants  266 174 156 89 110 85 
Incident anemia (n (%)) 60(25.6) 17(9.8) 51(32.7) 11(12.4) 9(8.2) 6(7.1) 
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months of ART follow-up. However, among ZDV 
group participants, despite having higher median 
hemoglobin concentration than non-ZDV group 
counterparts at baseline, there was increment of 
anemia prevalence from 20.8% at baseline to 
33.5% after six months of ART follow-up. This 
finding was supported by the finding of Zhou et al 
which indicated that patients initiated with ZDV-
containing ART had an increased risk of 
developing anemia when compared with those 
initiating non-ZDV containing ART regimens 
(31).
 
Table 4: Association of baseline characteristics with incident anemia after six months of ART follow up 
(n=256) at ART clinic of SPHMMC from February 2011 to December 2012. 
 
 
Variable  Incident Anemia p-value 






























































































Similarly, in this study, incident anemia was 
present among 32.7% and 12.4% of the ZDV 
group participants and 8.2% and 7.1% of the non-
ZDV group participants after six and twelve 
months of ART follow-up, respectively. A study 
conducted in the US reported that the incidence of 
anemia was 24.6 and 8.1 per 100 person years in 
ZDV and non ZDV cohorts after six months of 
follow-up. They also proved that the incidence 
was higher in ZDV cohorts than non-ZDV 
cohorts, and had highest incidence within six 
months of follow-up (15).   A study conducted at 
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St. Paul and ALERT hospitals in Addis Ababa, 
Ethiopia, also revealed 40.6 and 22.8 per 100 
person years incidence of anemia after six months 
of follow-up of ZDV and non-ZDV containing 
ART regimens, respectively(32). The observed 
difference may be due to the difference in the 
definition of anemia, methodology of the research 
(for example, the US study included ART 
experienced patients while the Ethiopian study 
included patients with opportunistic infections 
which could induce or exacerbate anemia 
themselves), as well as differences in population 
characteristics between Americans and 
Ethiopians.  
Zidovudine may also lead to macrocytosis of 
RBCs through its assumed mechanism of 
impairing the nuclear clock responsible for cell 
division thus causing enlarged cells to be 
produced (33). In this study, there was a 
remarkable proportion of macrocytic anemia 
development among the ZDV group (45.2% and 
72.7%) when compared to non-the ZDV group 
(11.1% and 16.7%) after six and twelve months of 
ART follow-up, respectively. Accordingly, ZDV 
group participants had a double risk of 
macrocytosis than their non-ZDV group 
counterparts after six months of ART follow-up.  
This was supported by other studies which 
revealed a higher incidence of macrocytosis 
among ZDV containing ART treated individuals 
than controls (33) and higher peripheral smear 
macrocytic changes after taking ZDV containing 
ART (30). 
The incidence of severe anemia in the ZDV 
group patients, 14.1%, was higher than reports 
from Uganda and Zimbabwe (6.6%) (4) and India 
(9.4%) (34). The observed difference may be due 
to variations in the definition of severe anemia 
(Hb≤6.5g/dl in the other studies and Hb<8g/dl in 
our study) and population heterogeneity. 
The strength of our study was the use of 
routine clinical data collected from a real life 
clinical setting to describe anemia comparatively 
among HIV/AIDS patients on ZDVand non-ZDV 
containing ART, on which information was 
limited among Ethiopian participants. However, 
the findings of this study should be considered 
alongside its limitations.  Since the data was 
collected from a routine ART service and the 
criteria of putting patients on the ZDV group or 
the non-ZDV group was merely based on the 
starting ART regimen, the study was not a strictly 
matched comparative study. In addition, we did 
not collected information on other clinical 
conditions that may be possible underlining  
causes of anemia at baseline.  Rather, we 
excluded those with identified opportunistic 
infections that could induce anemia themselves 
and pregnant women, since our main objective 
was to describe ZDV associated anemia.   
Generally, this study showed that there was a 
difference in anemia prevalence, severity and 
characteristics at initiation, after six months and 
twelve months of  ART follow-up among ZDV 
containing and non-ZDV containing ART drug 
regimen initiated participants. It revealed that 
ZDV had a significant contribution to severe 
anemia incidence within six months of ART 
follow-up, the majority of which were described 
as macrocytic anemia type. Thus, monitoring 
hemoglobin levels using simple and inexpensive 
hemoglobin measurement methods along with 
measurement of red cell indices over the first six 
months on ART is suggested for improved 
detection of ZDV associated anemia.  
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